James Brian Windsor

CIK: 0001790933

Transaction Breakdown

Open Market Buys (P)3 (60.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ALRN

Aileron Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

RNTX
Rein Therapeutics, Inc.
May 8, 2026
Award(A)
Stock Option (Right to Buy)
Direct
150K shares-
RNTX
Rein Therapeutics, Inc.
Apr 30, 2026
Purchase(P)
Direct
25K shares at avg. $1.00$25K
ALRN
Aileron Therapeutics, Inc.
Dec 5, 2024
Purchase(P)
Indirect
239 shares at avg. $2.24$535.36
ALRN
Aileron Therapeutics, Inc.
Dec 5, 2024
Purchase(P)
Indirect
161 shares at avg. $2.25$362.25
ALRN
Aileron Therapeutics, Inc.
Dec 2, 2024
Award(A)
Stock Option (right to buy)
Direct
517.5K shares-

		Type	Shares	Price		Ownership
May 8, 2026	RNTX Rein Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	150,000	-	-	Direct
Apr 30, 2026	RNTX Rein Therapeutics, Inc.	Purchase(P)	25,000	$1.00	$25,000	Direct
Dec 5, 2024	ALRN Aileron Therapeutics, Inc.	Purchase(P)	239	$2.24	$535	Indirect
Dec 5, 2024	ALRN Aileron Therapeutics, Inc.	Purchase(P)	161	$2.25	$362	Indirect
Dec 2, 2024	ALRN Aileron Therapeutics, Inc.	Award(A) Stock Option (right to buy)	517,500	-	-	Direct

1-5 of 5 transactions

About WINDSOR JAMES BRIAN

WINDSOR JAMES BRIAN (SEC CIK 0001790933) files insider reports with the SEC as President and CEO of Aileron Therapeutics, Inc. (ALRN).

Signal8 holds 3 ownership filings by WINDSOR JAMES BRIAN, all Form 4s, filed between Dec 4, 2024 and May 13, 2026. Those filings report 5 transactions, from Dec 2, 2024 to May 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on WINDSOR JAMES BRIAN's filings is in AUSTIN, TX.

Recent filings by WINDSOR JAMES BRIAN

May 8, 2026: Grant or award of RNTX derivative securities (Form 4, code A).
Apr 30, 2026: Open-market purchase of RNTX shares (Form 4, code P).
Dec 5, 2024: Open-market purchases of ALRN shares (2 lines, Form 4, code P).
Dec 2, 2024: Grant or award of ALRN derivative securities (Form 4, code A).

Other insiders filing for Aileron Therapeutics, Inc. (ALRN)

VON RICKENBACH JOSEF H, Director
Aivado Manuel, Director
Musso Alan A, Director
Fairey William, Director
Ambros Reinhard J., Director

How to read Form 4 transaction codes